Evaluation of a new, fully automated immunoassay for detection of HTLV‐I and HTLV‐II antibodies

Qiu, Xiaoxing; Hodges, Steven; Lukaszewska, Teresa; Hino, Shinjiro; Arai, Hiroyasu; Yamaguchi, Julie; Swanson, Priscilla; Schochetman, Gerald; Devare, Sushil G.

doi:10.1002/jmv.21083

Cited by 26 publications

(14 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The situation regarding HTLV-1 in Nicaragua and Costa Rica is poorly known but rare studies revealed similar relatively low HTLV-1 prevalence rates (0.2–0.7%), among the Nicaraguan and Costa Rican adult populations (Khabbaz et al, 1990; Qiu et al, 2008). In Belize, Guatemala and El Salvador, no HTLV-1 record about the prevalence of the HTLV-1 infection has been published to our knowledge.…”

Section: Htlv-1 Worldwide Distribution and Prevalence Estimates By Gementioning

confidence: 99%

Epidemiological Aspects and World Distribution of HTLV-1 Infection

Gessain¹,

Cassar²

2012

Front. Microbio.

1,147

1,152

View full text Add to dashboard Cite

The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world, with clusters of high endemicity located often nearby areas where the virus is nearly absent. The main HTLV-1 highly endemic regions are the Southwestern part of Japan, sub-Saharan Africa and South America, the Caribbean area, and foci in Middle East and Australo-Melanesia. The origin of this puzzling geographical or rather ethnic repartition is probably linked to a founder effect in some groups with the persistence of a high viral transmission rate. Despite different socio-economic and cultural environments, the HTLV-1 prevalence increases gradually with age, especially among women in all highly endemic areas. The three modes of HTLV-1 transmission are mother to child, sexual transmission, and transmission with contaminated blood products. Twenty years ago, de Thé and Bomford estimated the total number of HTLV-1 carriers to be 10–20 millions people. At that time, large regions had not been investigated, few population-based studies were available and the assays used for HTLV-1 serology were not enough specific. Despite the fact that there is still a lot of data lacking in large areas of the world and that most of the HTLV-1 studies concern only blood donors, pregnant women, or different selected patients or high-risk groups, we shall try based on the most recent data, to revisit the world distribution and the estimates of the number of HTLV-1 infected persons. Our best estimates range from 5–10 millions HTLV-1 infected individuals. However, these results were based on only approximately 1.5 billion of individuals originating from known HTLV-1 endemic areas with reliable available epidemiological data. Correct estimates in other highly populated regions, such as China, India, the Maghreb, and East Africa, is currently not possible, thus, the current number of HTLV-1 carriers is very probably much higher.

show abstract

Section: Htlv-1 Worldwide Distribution and Prevalence Estimates By Gementioning

confidence: 99%

Epidemiological Aspects and World Distribution of HTLV-1 Infection

Gessain¹,

Cassar²

2012

Front. Microbio.

1,147

1,152

View full text Add to dashboard Cite

show abstract

“…A variety of serological screening kits are available, including chemiluminescent enzyme immunoassays (CLEIAs), chemiluminescent immunoassays, and particle agglutination assays, followed by confirmation by Western blotting (WB) (5)(6)(7)(8)(9). WB measures the serological reaction to both Gag core proteins (p19, p24, and p53) and the Env protein gp46 (10).…”

mentioning

confidence: 99%

Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results

et al. 2017

View full text Add to dashboard Cite

Western blotting (WB) for human T cell leukemia virus type 1 (HTLV-1) is performed to confirm anti-HTLV-1 antibodies detected at the initial screening of blood donors and in pregnant women. However, the frequent occurrence of indeterminate results is a problem with this test. We therefore assessed the cause of indeterminate WB results by analyzing HTLV-1 provirus genomic sequences. A quantitative PCR assay measuring HTLV-1 provirus in WB-indeterminate samples revealed that the median proviral load was approximately 100-fold lower than that of WBpositive samples (0.01 versus 0.71 copy/100 cells). Phylogenic analysis of the complete HTLV-1 genomes of WB-indeterminate samples did not identify any specific phylogenetic groups. When we analyzed the nucleotide changes in 19 HTLV-1 isolates from WB-indeterminate samples, we identified 135 single nucleotide substitutions,

show abstract

“…CLIA (Qiu et al, 2008), and ECLIA (Laperche et al, 2017). These assays are available in Japan because they are capable of processing large numbers of samples in a relatively short time.…”

Section: Assays For Htlv-1 Antibody Screeningmentioning

confidence: 99%